FDA grants fast track designation for Priothera’s AML therapy
The new investigational drug, also known as KRP203, is a synthetic, sphingosine 1-phosphate receptor (S1PR) modulator. It has been evaluated in Phase I and Phase II trials for
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).
Under the collaboration, the company will use its AI drug discovery platform along with Denali Therapeutics’ expertise across the blood-brain barrier (BBB) and neurodegeneration for identifying therapeutically relevant